How ophthalmic drug delivery has moved from formulation chemistry to device engineering

What ophthalmic drug delivery looks like now

Drug delivery in ophthalmology spans several modalities:

Eye drops: The traditional front-of-eye and some posterior-segment delivery route. Limitations include patient adherence, ocular bioavailability (typically less than 5 percent of dose reaches target tissues), and the inability to deliver biologics effectively.

Intravitreal injection: The established posterior-segment delivery route, with substantial volume in retinal disease (wet AMD, DME, RVO, GA). Patient burden is the principal limitation: every 4 to 8 week injections in supervised clinical settings.

Sustained-release intravitreal implants: Devices implanted into the vitreous that release drug over months to years (dexamethasone implants, fluocinolone implants, others). Reduces injection frequency at the cost of implant procedure and device cost.

Port-delivery systems: Reservoir devices implanted in the eye that can be refilled in-office, providing continuous drug delivery between refills (ranibizumab port-delivery system).

Suprachoroidal delivery: Microneedle-based delivery into the suprachoroidal space, with strong posterior-segment access without intravitreal injection.

Microinvasive glaucoma surgery (MIGS) implants: Drug-eluting MIGS devices delivering pressure-lowering therapy via the anterior segment.

What is changing and why it matters

The shift from formulation chemistry to device engineering has several drivers:

• Patient burden in retinal disease is the principal commercial constraint on uptake. Reducing injection frequency is a substantial commercial axis
• Glaucoma adherence has been an unsolved problem with eye drops for decades. Device-based sustained delivery offers an adherence-independent option
• The biologic class cannot be delivered through eye drops in most current configurations. Device-based delivery is the practical path for biologic therapy in front-of-eye disease

The commercial implications across the modalities:

• Regulatory pathway is more complex for device-drug combinations than for either alone. The 505(b)(2) pathway and combination-product designations matter
• Manufacturing complexity is substantially higher for device-drug combinations than for conventional formulation chemistry
• The launch operating model includes specialist training, device-specific patient selection, and procedure-room workflow

What this means for commercial teams

For sponsors of ophthalmology assets in development:

• Device-drug combinations are increasingly the differentiation axis in retinal disease and in glaucoma
• The commercial planning has to integrate device manufacturing, specialist training, and procedure-room workflow alongside the molecular development
• Adjacent ophthalmology categories (front-of-eye disease, paediatric ophthalmology) are seeing device-based approaches enter the pipeline, with implications for what the next decade of commercial development looks like

What we are watching

• Late-stage device-drug combination programs across retinal disease and glaucoma
• Suprachoroidal-route delivery commercial uptake as approved assets establish the operational frame
• Adjacent indications (corneal disease, ocular surface disease) where device-based delivery is in earlier-stage development